Study of investigational drug combination for extensive small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new combination of investigational drugs (HS-20093) for people with extensive-stage small cell lung cancer whose disease hasn't progressed after initial treatment. The goal is to see if this approach can keep the cancer from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have extensive-stage small cell lung cancer (cancer that has spread beyond one lung).
- Your cancer has not gotten worse after your first standard treatment (chemotherapy plus immunotherapy).
- You are able to take care of yourself and do light activities (ECOG 0 or 1).
- You are willing to use effective birth control during and for 6 months after treatment (if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs for people with extensive-stage small cell lung cancer that has progressed after initial treatment. The goal is to see if this combination can help control the cancer.
This study tests a combination of three treatments for extensive-stage small cell lung cancer that has worsened after initial chemotherapy: an experimental pill, focused radiation (SBRT), and an immunotherapy drug. The goal is to see if this triple therapy can help the immune system fight the cancer more effectively.
This study is testing a new combination of two immunotherapy drugs (ivonescimab and cadonilimab) plus standard chemotherapy for extensive-stage small cell lung cancer. The goal is to see if this combination can be more effective than current treatments.
This trial tests a new combination treatment for extensive-stage small cell lung cancer: intensive chemotherapy plus an immunotherapy drug (adebrelimab), followed by a stem cell transplant using your own cells. The goal is to see if this powerful approach can shrink tumors and help you live longer.
This trial tests a new combination of drugs (chidamide, a PD-L1 inhibitor, carboplatin, and etoposide) as the first treatment for people with extensive-stage small-cell lung cancer. The goal is to see if this combination works better than standard treatments.
This trial tests a new drug (HS-20093) alone versus combined with another drug (adebrelimab) for people with advanced or metastatic non-squamous non-small cell lung cancer who have already been treated. The goal is to see if the combination works better at shrinking tumors or slowing cancer growth.
Hear when a new Extensive-stage Small Cell Lung Cancer (ES-SCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.